1. Homepagina
  2. Aandelen
  3. Nederland
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Nieuws
  7. Andere talen
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Rapport
Real Time Euronext Amsterdam  -  17:36 09-08-2022
53.00 EUR   -0.23%
08/08FMR groter in Galapagos
AM
08/08Galapagos ontvangt transparantieverklaring van FMR LLC
GL
08/08Galapagos ontvangt transparantieverklaring van FMR LLC
GL
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Nieuws in andere talen op GALAPAGOS NV
09/08GALAPAGOS : receives transparency notification from FMR LLC - Form 6-K
09/08GALAPAGOS : First key steps in pipeline rebuild and strong commercial progress in H1 2022 ..
08/08Galapagos receives transparency notification from FMR LLC
08/08Galapagos receives transparency notification from FMR LLC
05/08Galapagos Q2 Loss Narrows as Net Revenue Falls
05/08TRANSCRIPT : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
04/08First key steps in pipeline rebuild and strong commercial progress in H1 2022
04/08Galapagos NV Reports Earnings Results for the Half Year Ended June 30, 2022
25/07ACTUALIZACIÓN DE LAS FUERTES VARIACI : La adquisición de Bobst, Eutelsat se sale de la órb..
25/07POINT SUR LES FORTES VARIATIONS DU J : début de semaine en léger gain
25/07BOLSA DE MADRID : Embotellamientos de verano
25/07Embouteillages estivaux
25/07AVIS D'ANALYSTES DU JOUR : BNP Paribas, Adecco, Ubisoft, UCB, Crédit Agricole, Lonza, Sika..
23/06GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
23/06GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
22/06TRANSCRIPT : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call
22/06Pharmaceutical Group Galapagos Buys Cell Therapy Developers CellPoint, AboundBio For $2..
21/06Galapagos Expands Cell Therapy Capabilities Through Two Acquisitions
21/06Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
21/06Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
21/06Galapagos NV acquired CellPoint B.V. from ND Capital and others for approximately €..
21/06Galapagos NV acquired Abound Bio, Inc. for $14 million.
20/06Galapagos increases share capital through subscription right exercises
20/06Galapagos increases share capital through subscription right exercises
20/06Galapagos NV announced that it expects to receive €1.459507 million in funding
02/06GALAPAGOS : receives transparency notification from FMR LLC - Form 6-K
01/06Galapagos receives transparency notification from FMR LLC
01/06Galapagos receives transparency notification from FMR LLC
31/05GALAPAGOS : to showcase commitment to rheumatoid arthritis care at the upcoming European L..
25/05Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European ..
24/05Galapagos In-Licenses Drug Targets for Inflammatory Bowel Disease From Scipher
20/05Intervest Offices & Warehouses Extends Lease Deals For Office Portfolio In Belgium
06/05Galapagos creates new subscription right plans
06/05Galapagos creates new subscription right plans
06/05TRANSCRIPT : Galapagos NV, Q1 2022 Earnings Call, May 06, 2022
05/05Galapagos demonstrates regulatory and commercial progress in Q1 2022
05/05Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2022
28/04Galapagos NV Declares Voting Results
27/04GALAPAGOS : announces appointment of Dr. Paul Stoffels as Chairman of the board - Form 6-K
27/04Galapagos Names CEO As Chairman Under New Governance Structure
26/04Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
26/04Galapagos NV Announces Executive Appointments
12/04E-therapeutics Achieves Key Milestones Under Collaboration with Galapagos
12/04E-therapeutics plc Announces A Key Milestone in Its Collaboration with Galapagos
11/04SUBJECT : Galapagos AGM/EGM 2022 April 11th, 2022 - Form 6-K
11/04GALAPAGOS : Chairman letter to shareholders
01/04GALAPAGOS : Glpg egm & agm 2022
28/03Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION ..
28/03GALAPAGOS : nouvelle approbation pour Jyseleca au Japon
28/03Galapagos' Jyseleca Gets Japanese Nod For Ulcerative Colitis Treatment
28/03Jyselecaģ approved in Japan for ulcerative colitis
25/03GALAPAGOS : — Proposal of one-tier board structure & appointment of three new directo..
24/03GALAPAGOS : Statutory auditor's report on the non-consolidated financial statements per 31..
24/03CORRECTION : Galapagos publishes 2021 annual report and announces extraordinary and annual..
24/03Galapagos publishes 2021 annual report and announces extraordinary and annual sharehold..
24/03GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
21/03GALAPAGOS NV(ENXTAM : GLPG) dropped from FTSE All-World Index
18/03Galapagos increases share capital through subscription right exercises
01/03LES MARCHÉS EN TENSION : Emission du 1er mars 2022
25/02TRANSCRIPT : Galapagos NV, 2021 Earnings Call, Feb 25, 2022
25/02GALAPAGOS : 2021 results set stage for future growth - Form 6-K
24/02Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2021
24/02Galapagos 2021 results set stage for future growth
07/02GALAPAGOS : receives transparency notification from EcoR1 Capital - Form 6-K
07/02GALAPAGOS : provides further insights into the treatment of ulcerative colitis at the Euro..
03/02Galapagos receives transparency notification from EcoR1 Capital
02/02Galapagos provides further insights into the treatment of ulcerative colitis at the Eur..
02/02Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the Eur..
27/01Health Care Outperform Amid Fading Thursday Markets
27/01Top Midday Gainers
27/01Health Care Stocks Still Outperforming Amid Fading Thursday Markets
27/01SECTOR UPDATE : Health Care
27/01Galapagos Names Former Johnson & Johnson Executive Paul Stoffels CEO; Shares Soar
27/01GALAPAGOS : appoints Paul Stoffels as Chief Executive Officer - Form 6-K
27/01BOLSA DE MADRID : Oops ! He did it again ?
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op GALAPAGOS NV